Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection

Silvia Bulfone-Paus, Horst Von Bernuth, René Rückert, Joachim Wachtlin, Daniela Ungureanu, Michael Notter, Hans Krause, Thomas Pohl, Ralf Paus, Ulrich Kunzendorf

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumour transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-s g J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.

Original languageEnglish (US)
Pages (from-to)2707-2710
Number of pages4
JournalCancer Research
Volume58
Issue number13
StatePublished - Jul 1 1998
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection'. Together they form a unique fingerprint.

  • Cite this

    Bulfone-Paus, S., Von Bernuth, H., Rückert, R., Wachtlin, J., Ungureanu, D., Notter, M., Krause, H., Pohl, T., Paus, R., & Kunzendorf, U. (1998). Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection. Cancer Research, 58(13), 2707-2710.